Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +972-77-2005042 from 8 AM - 11 PM IL

    • Contact
    • Contact

      +972-77-2005042
      from 8 AM - 11 PM IL

  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR

Victor Papamoniodis Joins Medison Pharma as VP International Markets
  • USA - English
  • USA - Deutsch
  • USA - español
  • Latin America - español
  • USA - Français
  • Brazil - Português

MEDISON Logo

News provided by

Medison Pharma

20 Jan, 2022, 14:00 IST

Share this article

Share toX

Share this article

Share toX

ZUG, Switzerland, Jan. 20, 2022 /PRNewswire/ -- Medison, a global pharma company focused on providing access to highly innovative therapies to patients in international markets ("Medison"), is proud to announce the joining of Victor Papamoniodis in the newly created position of VP International Markets. Victor will be based in Zug, Switzerland, Medison's international headquarters.

Victor will head Medison's markets outside of Israel and will focus on scaling up the company's presence across markets, while growing and nurturing relationships with Medison's global partners.

Continue Reading
Victor Papamoniodis, VP International Markets, Medison Pharma
Victor Papamoniodis, VP International Markets, Medison Pharma

Prior to joining Medison, Victor held the position of VP International & Emerging Markets at Apellis Pharmaceuticals, Inc. Prior to that, he spent 9 years at Vertex Pharmaceuticals Incorporated as GM for Distributors & Expansion Markets, responsible for multiple regions, including CEE, LATAM, Russia & MENA.

"I am delighted to join Medison's global leadership at an exciting time of rapid growth and expansion into new markets. Medison creates a real paradigm shift in the pharma industry, positioning itself as the next-gen partner for biotech companies who wish to access international markets and serve patients in need," said Victor Papamoniodis.

"Medison is set out to change patients' lives in international markets, bridging the unbearable access gap and making the most innovative therapies accessible to patients," said Meir Jakobsohn, Founder and CEO of Medison. "The experience and capabilities that Victor brings will take our international platform to the next level."

"Adding Victor's capabilities will accelerate Medison's expansion into additional markets and regions, building a true unified platform for the benefit of partners and patients, globally," added Gil Gurfinkel, VP Corporate Development of Medison.

About Medison Pharma

Medison is a global pharma company focused on providing access to highly innovative therapies to patients in international markets. Medison is the first to create an international commercialization platform for highly innovative therapies, helping to save and improve lives by making the best available novel treatments accessible to patients in international markets. Medison has a track record of multi-territorial partnerships with leading pharmaceutical and biotech companies seeking to expand their global reach. To learn more visit www.medisonpharma.com. 

Photo - https://mma.prnewswire.com/media/1729991/Medison_Pharma_VP.jpg
Logo - https://mma.prnewswire.com/media/1527224/MEDISON_Logo.jpg

Medison Contact
Maya Nix
Corporate Communications Lead
[email protected]
+972-3-925-0260

Modal title

Also from this source

Health Canada Approves Bylvay™ (odevixibat) for the treatment of cholestatic pruritus in patients with Alagille Syndrome

Health Canada Approves Bylvay™ (odevixibat) for the treatment of cholestatic pruritus in patients with Alagille Syndrome

Medison and Ipsen announced today that Health Canada has approved Bylvay™ (odevixibat) for the treatment of cholestatic pruritus in patients 12...

Medison Expands Global Leadership Team with Chief Business Officer and Chief Legal & Compliance Officer

Medison Expands Global Leadership Team with Chief Business Officer and Chief Legal & Compliance Officer

Medison, the creator of a first-of-its-kind unified global commercialization platform that accelerates the launch of breakthrough therapies in...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Pharmaceuticals

Pharmaceuticals

Medical Pharmaceuticals

Medical Pharmaceuticals

Personnel Announcements

Personnel Announcements

News Releases in Similar Topics

Contact PR Newswire

  • +972-77-2005042
    from 8 AM - 11 PM IL

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Csezh
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italie
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+972-77-2005042
from 8 AM - 11 PM IL
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2025 Cision US Inc.